Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.

García-Calonge M, Castaño-García A, Piedra Cerezal AM, González Sánchez H, Muíño Domínguez D, Rodríguez M, Chiminazzo V, Varela Calvo M

Open source

DOI: 10.17235/reed.2025.11540/2025
Published: 2026 Sep
Container: Revista espanola de enfermedades digestivas
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.17235/reed.2025.11540/2025,
  title = {Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.},
  author = {García-Calonge M and Castaño-García A and Piedra Cerezal AM and González Sánchez H and Muíño Domínguez D and Rodríguez M and Chiminazzo V and Varela Calvo M},
  year = {2026},
  journal = {Revista espanola de enfermedades digestivas},
  doi = {10.17235/reed.2025.11540/2025},
  url = {https://doi.org/10.17235/reed.2025.11540/2025}
}

RIS

TY  - JOUR
TI  - Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.
AU  - García-Calonge M
AU  - Castaño-García A
AU  - Piedra Cerezal AM
AU  - González Sánchez H
AU  - Muíño Domínguez D
AU  - Rodríguez M
AU  - Chiminazzo V
AU  - Varela Calvo M
PY  - 2026
JO  - Revista espanola de enfermedades digestivas
DO  - 10.17235/reed.2025.11540/2025
UR  - https://doi.org/10.17235/reed.2025.11540/2025
ER  -

APA

M, G., A, C., AM, P. C., H, G. S., D, M. D., M, R., V, C., & M, V. C. (2026). Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.. Revista espanola de enfermedades digestivas. https://doi.org/10.17235/reed.2025.11540/2025

Source records

pubmed · retrieved 2026-09-26T10:35:18.026Z